For U.S. Residents Only
Indication
MULTAQ is a prescription medicine used to lower the chance you would need to go into the hospital for an irregular heart rhythm called atrial fibrillation (AFib). It is meant for people who have had AFib in the past but are now in normal heart rhythm.
img img img img

About Multaq

Not actual patients.

MULTAQ AT A GLANCE

MULTAQ® is a medication used in patients with certain types of atrial fibrillation (paroxysmal or persistent AFib) to lower the chance they will need to go into the hospital for AFib. MULTAQ can help keep the heart beating in normal rhythm longer, which may help patients have more days without AFib episodes.

TALK WITH YOUR DOCTOR ABOUT YOUR AFIB TREATMENT PLAN

If you are already on treatment for AFib, but are still having episodes, there may be more you and your doctor can do to help manage them. Once you are in regular rhythm, MULTAQ may be a treatment option that can help you stay in normal rhythm longer.

Download our Discussion Guide to start the conversation with your doctor to better understand normal rhythm and how MULTAQ may help.

HOW CAN MULTAQ HELP?

In two clinical studies in patients with AFib, MULTAQ results included:

Two horizontal bars with the text,  "2.2X LONGER"

In the 12-month study, MULTAQ kept patients in normal heart rhythm 2.2 times longer than patients taking placebo • 116 days for patients on MULTAQ vs 53 days for patients on placebo

In the 12-month study, MULTAQ kept patients in normal heart rhythm 2.2 times longer than patients taking placebo • 116 days for patients on MULTAQ vs 53 days for patients on placebo

In the 12-month study, MULTAQ lowered the chance of an AFib event • 64.1% of patients on MULTAQ had an AFib event, compared to 75.2% of patients on placebo

In the 12-month study, MULTAQ lowered the chance of an AFib event • 64.1% of patients on MULTAQ had an AFib event, compared to 75.2% of patients on placebo

In another study, MULTAQ lowered the chance of either heart-related hospitalizations or death by 24% compared to placebo

• Result is based only on reduction of CV hospitalization. 31.6% of patients on MULTAQ had either heart-related hospitalization or death compared to 39.2% of patients on placebo

• Result is based only on reduction of CV hospitalization. 31.6% of patients on MULTAQ had either heart-related hospitalization or death compared to 39.2% of patients on placebo

The American Heart Association, American College of Cardiology, and Heart Rhythm Society recommend MULTAQ and medicines like it to help maintain normal heart rhythm for patients with AFib.

Your doctor is your best source for determining which medicines are right for you.

Sinus rhythm is when your heart is pumping blood and at a "normal" rate. When it is not,you may have AFib. Paroxysmal AFib is an episode that lasts less than a week. You might feel it for a few minutes, or a few days. Persistent AFib is an episode that lasts more than a week, but less than a year. Do not take MULTAQ if you have a type of AFib called permanent AFib.